Get Stock Quote Here Endo International plc (ENDP) is global specialty healthcare company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called "Endo Pharmaceuticals Inc." Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQ: ENDP). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt. On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company. Endo and Paladin Labs came together under Endo International plc and Endo established new global headquarters in Dublin, Ireland. Endo develops, manufactures, markets and distributes quality branded pharmaceutical, generic and device products though its operating companies. The company has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.
Reported after close today (5/5/16) Earnings: EPS $1.08 Revenue $963.5M Estimates: EPS $1.05 Revenue $964.4M Down 22.45% after hours
Up over 18% today Endo International Jumps on Patent Approval, Still Has Work to Do Read full article here: http://realmoney.thestreet.com/arti...ional-jumps-patent-approval-still-has-work-do
$ENDP Cut right through the 150 day moving average. Nice consolidation just below the highs made for a nice day trade
Endo's profit, revenue top estimates on strong generic drug sales * Q3 adjusted EPS, sales top estimates * U.S. generics drug sales surge 45 percent * Company reaffirms full-year forecast * Shares up 4.2 percent premarket (Adds details on results, background; updates shares) Nov 8 (Reuters) - Endo International Plc reported quarterly revenue and adjusted profit that blew past analysts' estimates, driven by higher demand for the generic drugs it acquired when it bought Par Pharmaceuticals last year. Shares of Endo, which offers a suite of specialty, generic and over-the-counter medical products, were up 4.3 percent at $16.35 in premarket trading on Tuesday. Endo's revenue from its U.S. generic drug business rose 45 percent to $534 million in the third quarter as the demand for Par Pharma's drugs offset a drop in sales at Endo's legacy generics business. The overall generics business, which accounted for about 60 percent of total revenue, was led by Paul Campanelli until he became chief executive of Endo in September. Campanelli joined Endo following the company's $8-billion acquisition of Par Pharma, where he was CEO since 2012. The growth in the U.S. generics business also helped offset a decline in sales at Endo's other divisions - U.S. branded pharmaceuticals and international pharmaceuticals. The company's total revenue rose 18.6 pct to $884.3 million in the three months ended Sept. 30, beating analysts' average estimate of $862.3 million, according to Thomson Reuters I/B/E/S. Excluding items, Dublin, Ireland-based Endo earned $1.01 per share, handily beating analysts' average estimate of 81 cents. The drugmaker's net loss attributable to shareholders narrowed to $218.9 million, or 98 cents per share, from $1.05 billion, or $5.02 per share, a year earlier. Endo, much like its Canadian peer Valeant Pharmaceuticals International Inc , is reeling with a large debt load and facing mounting pressure over its pricing strategies, after years of relying on acquisitions to juice growth. Valeant on Tuesday reported a smaller-than-expected quarterly adjusted profit due to faltering sales of its dermatology products and bowel drug, and the company cut its full-year profit and revenue forecasts. Endo reaffirmed its full-year revenue and profit forecast. The company has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical unit, to Canadian drug maker Knight Therapeutics Inc, Reuters reported last week, citing sources. Endo net debt totaled $7.7 billion as of Sept. 30. (Reporting by Natalie Grover and Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta and Savio D'Souza)
Shares of Endo International (NASDAQ:ENDP) have been under pressure just like every other biotech/pharma has been. That is about to end. The stock has multiple bullish signals on the chart and may have 50% upside in the next month. Note on the stock chart below how the stock is putting in a bull flag, slow consolidation pattern. In addition, secondarily note how the stock has been making higher lows over the last six months. This is very bullish. In addition, all investors should be aware that biotech/pharma stocks like Endo International are seeing tax loss selling into year end. Once December come to a close, those sellers will vanish. This is where the big upside looms. I expect the stock to be $22 in late January - February 2017.
Soon to be President Donald Trump gave investors a gift. The smart ones could not refuse. The Donald trashed biotech in his press conference causing a massive sell-off. Select biotech stocks that took a beaten, hit major support levels and offered investors an extremely cheap valuation buying level. In my opinion, this is the case with Endo International plc (NASDAQ:ENDP). The stock flushed into a major double bottom support level at $13.75. Based on valuation metrics, this is down right cheap. In addition, this tough talk on biotech drug pricing is nothing new. It has been going on for well over a year. In my opinion, there is little downside left as everything has been factored in. I believe this was a gift buying opportunity on many biotechnology stocks like Endo International plc (NASDAQ:ENDP). Others that are interesting are Gildead Sciences, Valeant Pharma and Teva Pharma.
Thanks to some new screen filters from JerryM, i watched ENDP, rise $.40. Wish i was in it. I would have been happy with $.25, Thanks Jerry BW
Nice break out over Feb highs today, Im hopeful this is the beginning of a change in longer term trend.
Some Hulk-sized volume the last 2 days. Citron saying this can make $10, is the anti-Mallinckrodt in terms of opioids.
